Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 191382, 9 pages
http://dx.doi.org/10.1155/2015/191382
Research Article

Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy

1NIHR Moorfields Biomedical Research Centre, London EC1V 2PD, UK
2King’s College Hospital NHS Foundation Trust, London SE5 9RS, UK
3Department of Epidemiology and Biostatistics, University of Athens, 11528 Athens, Greece
4King’s College London, London SE5 9RS, UK

Received 29 May 2015; Revised 11 July 2015; Accepted 14 July 2015

Academic Editor: Steven F. Abcouwer

Copyright © 2015 Roxanne Crosby-Nwaobi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Klein, B. E. K. Klein, S. E. Moss, and K. J. Cruickshanks, “The Wisconsin epidemiologic study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy,” Archives of Ophthalmology, vol. 112, no. 9, pp. 1217–1228, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Antonetti, R. Klein, and T. W. Gardner, “Diabetic retinopathy,” The New England Journal of Medicine, vol. 366, no. 13, pp. 1227–1239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. L. P. Aiello and DCCT/EDIC Research Group, “Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study,” Diabetes Care, vol. 37, no. 1, pp. 17–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. I. P. Chatziralli, T. N. Sergentanis, P. Keryttopoulos, N. Vatkalis, A. Agorastos, and L. Papazisis, “Risk factors associated with diabetic retinopathy in patients with diabetes mellitus type 2,” BMC Research Notes, vol. 3, article 153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Simó and C. Hernández, “Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence,” Progress in Retinal and Eye Research, 2015. View at Publisher · View at Google Scholar
  6. D. V. Do, X. Wang, S. S. Vedula et al., “Blood pressure control for diabetic retinopathy,” The Cochrane Database of Systematic Reviews, vol. 1, Article ID CD006127, 2015. View at Publisher · View at Google Scholar
  7. J. Xie, E. K. Fenwick, Y. Taouk, and et al, “Relative importance and contribiton of risk factors for diabetic retinopathy and macular edema,” Journal of Diabetes & Metabolism, vol. 5, article 337, 2014. View at Publisher · View at Google Scholar
  8. Y.-C. Chang and W.-C. Wu, “Dyslipidemia and diabetic retinopathy,” Review of Diabetic Studies, vol. 10, no. 2-3, pp. 121–132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Keech, R. J. Simes, P. Barter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, pp. 1849–1861, 2005. View at Publisher · View at Google Scholar
  10. ACCORD Study Group, ACCORD Eye Study Group, E. Y. Chew et al., “Effects of medical therapies on retinopathy progression in type 2 diabetes,” The New England Journal of Medicine, vol. 363, no. 3, pp. 233–244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Y. Wong, R. Simó, and P. Mitchell, “Fenofibrate—a potential systemic treatment for diabetic retinopathy?” The American Journal of Ophthalmology, vol. 154, no. 1, pp. 6–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Simó, S. Roy, F. Behar-Cohen, A. Keech, P. Mitchell, and T. Y. Wong, “Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives,” Current Medicinal Chemistry, vol. 20, no. 26, pp. 3258–3266, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Tomić, S. Ljubić, and S. Kaštelan, “The role of inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy,” Collegium Antropologicum, vol. 37, no. 1, pp. 51–57, 2013. View at Google Scholar · View at Scopus
  14. R. Simó, J. M. Sundstrom, and D. A. Antonetti, “Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy,” Diabetes Care, vol. 37, no. 4, pp. 893–899, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Kato, H. Osawa, M. Ochi et al., “Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy,” Clinical Endocrinology, vol. 68, no. 3, pp. 442–449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. I. Yilmaz, A. Sonmez, C. Acikel et al., “Adiponectin may play a part in the pathogenesis of diabetic retinopathy,” European Journal of Endocrinology, vol. 151, no. 1, pp. 135–140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Uckaya, M. Ozata, Z. Bayraktar, V. Erten, N. Bingol, and I. C. Ozdemir, “Is leptin associated with diabetic retinopathy?” Diabetes Care, vol. 23, no. 3, pp. 371–376, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Joussen, S. Doehmen, M. L. Le et al., “TNF-α mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations,” Molecular Vision, vol. 15, pp. 1418–1428, 2009. View at Google Scholar · View at Scopus
  19. J. Arrants, “Hyperinsulinemia and cardiovascular risk,” Heart and Lung, vol. 23, no. 2, pp. 118–122, 1994. View at Google Scholar · View at Scopus
  20. M. B. Sasongko, T. Y. Wong, T. T. Nguyen et al., “Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids,” Diabetes Care, vol. 34, no. 2, pp. 474–479, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. R. R. Crosby-Nwaobi, S. Sivaprasad, S. Amiel, and A. Forbes, “The relationship between diabetic retinopathy and cognitive impairment,” Diabetes Care, vol. 36, no. 10, pp. 3177–3186, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. P. Wilkinson, F. L. Ferris III, R. E. Klein et al., “Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales,” Ophthalmology, vol. 110, no. 9, pp. 1677–1682, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Kinyoun, F. Barton, M. Fisher, L. Hubbard, L. Aiello, and F. Ferris III, “Detection of diabetic macular edema. Ophthalmoscopy versus photography—early treatment diabetic retinopathy study report number 5. The ETDRS Research Group,” Ophthalmology, vol. 96, no. 6, pp. 746–750, 1989. View at Google Scholar
  24. X. Provatopoulou, D. Georgiadou, T. N. Sergentanis et al., “Interleukins as markers of inflammation in malignant and benign thyroid disease,” Inflammation Research, vol. 63, no. 8, pp. 667–674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. A. K. Sjølie, R. Klein, M. Porta et al., “Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial,” The Lancet, vol. 372, no. 9647, pp. 1385–1393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. H. Gallego, M. E. Craig, S. Hing, and K. C. Donaghue, “Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study,” British Medical Journal, vol. 337, article a918, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-H. Jung, B.-Y. Kim, J.-O. Mok, S.-K. Kang, and C.-H. Kim, “Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus,” Journal of Diabetes Investigation, vol. 5, no. 3, pp. 333–339, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. A. Hill and M. J. McQueen, “Reverse cholesterol transport—a review of the process and its clinical implications,” Clinical Biochemistry, vol. 30, no. 7, pp. 517–525, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Hu, Y. Luo, T. Li et al., “Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 7, pp. 957–962, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. McQueen, S. Hawken, X. Wang et al., “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study,” The Lancet, vol. 372, no. 9634, pp. 224–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. S. M. Boekholdt, G. K. Hovingh, S. Mora et al., “Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials,” Journal of the American College of Cardiology, vol. 64, no. 5, pp. 485–494, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Yokoi, S.-I. Yamagishi, M. Takeuchi et al., “Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy,” British Journal of Ophthalmology, vol. 89, no. 6, pp. 673–675, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. D. N. Koleva-Georgieva, N. P. Sivkova, and D. Terzieva, “Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy,” Folia Medica, vol. 53, no. 2, pp. 44–50, 2011. View at Google Scholar · View at Scopus
  34. S. K. Paine, A. Sen, S. Choudhuri et al., “Association of tumor necrosis factor α, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects,” Retina, vol. 32, no. 6, pp. 1197–1203, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Daviaud, J. Boucher, S. Gesta et al., “TNFα up-regulates apelin expression in human and mouse adipose tissue,” The FASEB Journal, vol. 20, no. 9, pp. 1528–1530, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. C. A. Aveleira, C.-M. Lin, S. F. Abcouwer, A. F. Ambrósio, and D. A. Antonetti, “TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability,” Diabetes, vol. 59, no. 11, pp. 2872–2882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Huang, J. K. Gandhi, X. Zhong et al., “TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis,” Investigative Ophthalmology and Visual Science, vol. 52, no. 3, pp. 1336–1344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. L. P. Aiello, “Vascular endothelial growth factor and the eye. Past, present and future,” Archives of ophthalmology, vol. 114, no. 10, pp. 1252–1254, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Jain, S. Saxena, V. K. Khanna, R. K. Shukla, and C. H. Meyer, “Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus,” Molecular Vision, vol. 19, pp. 1760–1767, 2013. View at Google Scholar · View at Scopus
  40. N. Baharivand, N. Zarghami, F. Panahi, M. Y. Dokht Ghafari, A. M. Fard, and A. Mohajeri, “Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy,” Clinical Ophthalmology, vol. 6, no. 1, pp. 185–191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. R. O. Schlingemann, C. J. F. Van Noorden, M. J. M. Diekman et al., “VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes,” Diabetes Care, vol. 36, no. 6, pp. 1629–1634, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Celebiler Cavusoglu, S. Bilgili, A. Alaluf et al., “Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy,” Annals of Ophthalmology, vol. 39, no. 3, pp. 205–208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. C. M. G. Cheung, M. Vania, M. Ang, S. P. Chee, and J. Li, “Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy,” Molecular Vision, vol. 18, pp. 830–837, 2012. View at Google Scholar · View at Scopus
  44. H. Funatsu, H. Yamashita, H. Noma et al., “Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 1, pp. 3–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Hernández, R. M. Segura, A. Fonollosa, E. Carrasco, G. Francisco, and R. Simó, “Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy,” Diabetic Medicine, vol. 22, no. 6, pp. 719–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Yoshimura, K.-H. Sonoda, M. Sugahara et al., “Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases,” PLoS ONE, vol. 4, no. 12, Article ID e8158, 2009. View at Publisher · View at Google Scholar · View at Scopus